Publications by authors named "Kirsten Hagen"
Background: Cerebrovascular disease is a common cause of dementia in older adults, and potentially preventable with early intervention. Oxylipins are produced from the oxidation of long-chain polyunsaturated fatty acids (PUFA) possessing potent vascular effects. Oxylipins generated from the cytochrome P450 pathway are enzymatically converted to diols by soluble epoxide hydrolase (sEH); sEH products have been associated with small vessel ischemic disease.
View Article and Find Full Text PDFAim: The Meals, Mindfulness, & Moving Forward (M ) programme included nutrition education, hands-on cooking classes, mindfulness meditation practice, physical activities and facilitated group sharing. M was designed as a supplement to standard care for youths (age 15-25 years) with first-episode psychosis (FEP) who were clients of coordinated specialty care teams. M 's primary aim was feasibility by demonstrating high programme attendance; secondary aims included cardiometabolic measures.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how managing vascular risk factors could help prevent age-related cognitive decline, focusing on the effects of marine n-3 polyunsaturated fatty acids (n-3 PUFA) on white matter hyperintensities (WMH), which are associated with cognitive issues.
- Conducted as a randomized, double-blind trial, 102 older adults (average age 81) were given either n-3 PUFA or a placebo to analyze changes in WMH over three years, with safety and efficacy also being assessed.
- The research specifically explores the relationship between n-3 PUFA levels, WMH volume, and inflammation markers, aiming to find insights
Aim: The primary aim was to demonstrate adherence to a novel 6-week lifestyle intervention program ("Meals, Mindfulness, & Moving Forward" [M ]) designed to help improve lifestyle practices of youth with a history of at least 1 psychotic episode.
Methods: M used a non-equivalent control group design involving clients from a community early intervention program. Seventeen individuals in the active M program and 16 controls were assessed for secondary outcomes at baseline, 6-weeks, and 12-weeks (6 weeks post-intervention) on cardiometabolic and symptomatic outcomes.